In a breakthrough for incretin medicines, China’s National Medical Products Administration (NMPA) has approved Innovent’s ...

VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

Abstract Title: First-in-Class Oral Dual GLP-1/Glucagon Agonist for Patients with Obesity and Metabolic Disorders: In Vivo Pharmacokinetic and Pharmacodynamic Results Presentation Number: SUN-680 ...

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...

A clinical trial for semaglutide, the active ingredient in Ozempic, found that it improved blood sugar control in people with ...

Liraglutide, a member of the family of blockbuster weight-loss drugs, reduces headaches by half in a small study.

By 2023, in which 93,121 adolescents were diagnosed with obesity, the mean (SD) ages were 14.4 (1.7) years overall, but 15.2 (1.6) years among those prescribed obesity medication (n = 427).

A new algorithm enables smartwatch fitness trackers to more accurately monitor energy expenditure of people with obesity ...

Despite an increase in the prevalence of prescribing, only 0.5% of U.S. adolescents with obesity were prescribed an obesity medication in 2023, according to research published in the June 5 issue ...

Higher prevalence of prescribing was seen among girls than boys (adjusted prevalence ratio [aPR], 2.05), adolescents aged 15 to 17 vs 12 to 14 years (aPR, 2.24), and among those with class 2 or 3 ...

Obesity remains one of the greatest health challenges worldwide, leading to diabetes, heart disease, and increased healthcare ...